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Abstract
Hepatitis remains as clinical challenge and a problem of great importance in developing and underdeveloped world. Acute hepatitis
can have serious health effects including mortality. There is no specific treatment for acute hepatitis. Care is aimed at maintaining
comfort and adequate nutritional balance. Lycopene is a potent antioxidant of carotenoid family found in fruits and vegetables. The
consumption of lycopene-rich foods, such as tomato paste, chilli sauce, and spaghetti sauce, has been demonstrated to prevent the
occurrence of a number of chronic diseases including various types of cancers. Lycopene has been associated with a number of
health benefits particularly in regard to prostate, lung, heart and skin health. The present investigation was carried upon to explore the
role of lycopene on liver health by analyzing the biochemical parameters and liver marker enzymes during experimentally induced
hepatitis in animal model and the findings strongly suggest that lycopene is potential agent of hepatoprotection.
© 2013 Taibah University. Production and hosting by Elsevier B.V. All rights reserved.
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1. Introduction
The viral hepatitis particularly, Hepatitis B is the
most common form of acute hepatitis. Hepatitis B virus
(HBV) is a major cause of acute hepatitis, cirrhosis and
hepatocellular carcinoma worldwide. HBV continues to
be the single most important cause of viral hepatitis in
the developing and underdeveloped world. It is estimated
that about one-third of the global population, around 2
billion people have been infected with the hepatitis B∗ Corresponding author at: Department of Biochemistry, College of
Applied Medical Sciences, Shaqra University, Post Box No. 1383,
Shaqra 11961, Saudi Arabia. Tel.: +966 592069545.
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http://dx.doi.org/10.1016/j.jtusci.2013.01.002virus at some stage in their lifetime. Of these, about 360
million people remain chronically infected carriers of
the disease. According to World Health Organisation
(WHO) report [62], an estimated 600,000 persons die
each year due to the acute or chronic consequences of
hepatitis B. Hepatitis remains as clinical challenge and
a problem of great importance. Acute hepatitis can have
serious health effects including mortality. There is no
specific treatment for acute hepatitis. Care is aimed at
maintaining comfort and adequate nutritional balance
[22].
Carotenoids are a class of more than 600 natural
pigments that are present in fruits and vegetables [23].
Epidemiological reports demonstrate a clear inverse
association between diets high in carotenoid-rich fruits
and vegetables and reduced incidence of variety of
diseases [59,60]. Lycopene is a potent antioxidant of
carotenoid family, and naturally occurring compound
that gives characteristic red color to tomato, watermelon,
pink grapefruit, orange, and apricot [51]. A number of
studies have indicated the health benefits of consum-
ing lycopene and demonstrated its preventive role in
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he occurrence of a number of chronic diseases includ-
ng various types of cancers [17,24,16,12,1,11,57].
ycopene is found to be the most effective antioxi-
ant among all the tested carotenes and xanthophylls
36,13]. Among the numerous models of experimental
epatitis, d-GalN induced liver damage is very similar
o human viral hepatitis in its morphological and func-
ional features [31]. Administration of a subtoxic dose
f galactosamine (GalN) together with or followed by
ipopolysaccharide (LPS) induces acute hepatitis and is
well-established model for acute hepatitis [4,63,41].
his liver injury model has been used to evaluate the
herapeutic value of flavones, quinines and carotenoids
hat are known as antioxidants and of other plant products
hat are claimed to be hepatoprotective [39,19,29].
Despite considerable progress in the treatment of
iver diseases by oral hepatoprotective agents, search for
ewer drugs continues because the existing synthetic
rugs have several limitations. Hence crude drugs or
atural food diet which possesses antioxidant or free
adical scavenging activity has become a central focus
or research designed to prevent or ameliorate tissue
njury and may have a significant role in maintaining
ealth. The scientific research to date has demon-
trated an array of health benefits clearly associated with
ycopene. It offers important health benefits particularly
n regard to prostate, lung, heart and skin health. In
ur preliminary investigation we have earlier reported
he role of lycopene on liver health in experimental
nimals [52,49,50]. Thus the present investigation fur-
her explores the hepatoprotective role of lycopene by
nalyzing the biochemical parameters and liver marker
nzymes during d-GalN/LPS induced liver injury.
. Materials and methods
.1. Chemicals
d-GalN and LPS (Sero type 011.B4 extracted by phe-
ol water method from Escherichia coli) were obtained
rom Sigma Chemical Co. (St. Louis, MO, USA). All
ther chemicals (acids, bases, solvents and salts) used
ere of analytical grade obtained from Sisco Research
aboratories Pvt. Ltd., Mumbai, India and Glaxo Lab-
ratoreis, CDH division, Mumbai, India. Jagsonpal
harmaceuticals, New Delhi, India, kindly provided
ycopene..1.1. Lycopene stock solution
Lycopene (100 mg) was mixed in 2 ml Tween-80
t room temperature until a homogeneous paste was
btained. Physiologic saline at room temperature wasniversity for Science 7 (2013) 8–16 9
added, drop wise and with vigorous stirring, to a final
concentration of 10 mg lycopene/ml of suspension [35].
2.2. Animals
Adult male albino rats of Wistar strain weighing
around 120–150 g obtained from Tamil Nadu Veteri-
nary and Animal Sciences University (TANUVAS),
Madhavaram, Chennai, India were used in this study.
They were housed in polypropylene cages over husk
bedding and a 12 h light and dark cycle was main-
tained throughout the experimental period. Rats were
fed a commercial pelleted diet (Hindustan Lever Lim-
ited, Bangalore, India) and water ad libitum. The
experiments were conducted according to the ethi-
cal norms approved by Ministry of Social Justices
and Empowerment, Government of India and Institu-
tional Animal Ethics Committee guidelines (IAEC No.
01/026/08).
2.3. Experimental design
The animals were divided into four groups of six
animals each.
Group 1: Served as vehicle control and was adminis-
tered with Tween-80 in saline.
Group 2: Rats were given lycopene alone (10 mg/kg
body weight for 6 days intraperitoneally).
Group 3: Rats were induced with d-GalN and LPS
(300 mg/kg body weight and 30g/kg body weight,
i.p 18 h before the experiment) [42].
Group 4: Rats were pretreated with lycopene for 6 days
prior to the induction of d-GalN/LPS.
2.4. Collection of samples for biochemical analysis
After the experimental period, the animals were
anaesthetized by intraperitoneal injection of pentobar-
bital sodium (30 mg/kg body weight) and sacrificed.
Blood was collected and the liver tissue was excised
quickly. The tissues were immediately washed in phys-
iological saline to remove blood clot and other tissue
materials and stored at 4 ◦C until further use.
2.5. Separation of serumThe blood samples collected in plain centrifuge
tubes were kept in inclined position to allow complete
clotting of blood and then centrifuged at 2500 rpm for
30 min. The resultant clear supernatant was pipetted
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Figs. 1 and 2 depict the levels of urea, ammonia, uric
acid and creatinine in control and experimental animals.
Blood urea and serum uric acid levels were significantly10 S.A. Sheriff, T. Devaki / Journal of T
out and preserved in small vials in the freezer for the
purpose of biochemical investigations.
2.6. Preparation of liver homogenate
Within 3 h after sacrifice, liver samples were blot-
ted to dryness. From this, a piece weighing about
100 mg was taken and homogenized at 4 ◦C in Tris–HCl
buffer (0.1 M, pH 7.4). The tissue homogenates were
centrifuged at 2500 rpm for 30 min. The resultant
supernatant was kept under refrigeration until further
biochemical analysis. All the assay procedures were car-
ried out within 48 h after sample collection.
2.7. Estimation of urea, ammonia, uric acid,
creatinine and bilirubin
The blood urea and ammonia were determined by
the methods of Natelson et al. [41] and Kingsley and
Tager [28] respectively. Their values were expressed as
mg/dl in blood. Uric acid, creatinine and bilirubin were
estimated in the serum according to the method of Car-
away [10], Broad and Sirota [9] and Malloy and Evelyn
[33] respectively. The values were expressed as mg/dl of
serum.
2.8. Estimation of glucose, glycogen, lactate and
pyruvate
Blood glucose was estimated by the method of Sasaki
and Matsui [48]. The values were expressed as mg/dl
blood. Liver glycogen was estimated by the method of
Morales et al., [38]. The values were expressed as mg/g
tissue. The lactate and pyruvate content of liver was esti-
mated by the methods of Barker and Summerson [7] and
Friedemann and Haugen [15] respectively. Their values
were expressed as g/mg protein.
2.9. Estimation of iron and ferritin
Iron content was estimated by the method of Ramsay
[44]. The iron content of ferritin in liver was estimated
by the method of Drysdale and Munro [14]. The results
were expressed as g/g wet liver.
2.10. Assay of diagnostic liver markers enzymes
The method of Reitman and Frankel [46] was adopted
for the assay of asparate transaminase (AST) and ala-
nine transaminase (ALT). These enzyme activities
were expressed as moles of pyrvuate liberated/h/mg
protein for tissue. Alkaline phosphatase was assayed byniversity for Science 7 (2013) 8–16
the method of Kind and King [25]. Acid phosphatase
(ACP) was assayed by the method of King [26]. Their
activities were expressed as moles of phenol liber-
ated/h/mg protein for tissue. The assay of -glutamyl
transferase (GT) was carried out by the method of
Rosalki and Rau [47]. Lactate dehydrogenase (LDH)
was assayed according to the method of King [27]. The
enzyme activity was expressed as moles of pyrvuate
liberated/h/mg protein for tissue.
2.11. Histopathological studies
Small pieces of liver tissues were collected in 10%
formal saline for proper fixation. These tissues were
processed, embedded in paraffin wax sections of 5–6m
thick, cut and stained with hematoxylin and eosin. The
sections were examined under light microscope and pho-
tomicrographs were obtained.
2.12. Statistical analysis
All the grouped data were statistically evaluated with
Statistical Package for Social Sciences (SPSS), Version
10.0. Hypothesis testing methods included one way anal-
ysis of variance (ANOVA) followed by least significant
difference (LSD) test. A ‘P’ value of less than 0.05 was
considered to indicate statistical significance. All the
results were expressed as mean ± S.D. for six animals
in each group.
3. Results
3.1. Urea, ammonia, uric acid and creatinineFig. 1. Levels of urea and ammonia in control and experimental group
of animals. Values are expressed as mean ± SD for six rats in each
group. a As compared with group 1 (control), b As compared with
group 3 (D-GalN/LPS); a,b represent P < 0.05. (Ly-lycopene).
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Fig. 2. Levels of uric acid and creatinine in control and experimental
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Fig. 3. Levels of glucose in control and experimental group of animals.
Values are expressed as mean ± SD for six rats in each group. a As
compared with group 1 (control), b As compared with group 3 (D-
GalN/LPS); a,b represent P < 0.05. (Ly-lycopene).
Fig. 4. Levels of glycogen in the liver of control and experimental
group of animals. Values are expressed as mean ± SD for six rats in
each group. a As compared with group 1 (control), b As compared with
a,b
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Vroup of animals. Values are expressed as mean ± SD for six rats in
ach group. a As compared with group 1 (control), b As compared with
roup 3 (D-GalN/LPS); a,b represent P < 0.05. (Ly-lycopene).
ecreased (P < 0.05) whereas blood ammonia and
erum creatinine levels were significantly increased
P < 0.05) in rats induced with d-GalN/LPS (Group 3).
he above changes were reversed to near normal levels
n rats treated with lycopene prior to the toxic insult
f d-GalN/LPS (Group 4). Group 2 rats treated with
ycopene alone did not show any significant alteration in
hese parameters when compared to control (Group 1).
.2. Bilirubin
Table 1 depicts serum levels of total, conjugated
nd unconjugated bilirubin in control and experimen-
al groups of rats. Rats injected with d-GalN/LPS
Group 3) showed a significant elevation (P < 0.05) in
otal and conjugated bilirubin with subsequent reduction
P < 0.05) in unconjugated bilirubin when compared to
ontrol (Group 1). Pretreatment with lycopene (Group 4)
esulted in reversal of above changes to near normal. Rats
reated with lycopene alone (Group 2) did not show any
ignificant changes in bilirubin levels when compared to
ontrol..3. Glucose, glycogen, lactate and pyruvate
Figs. 3–5 represent the levels of glucose, glycogen,
actate and pyruvate in control and experimental groups
able 1
evels of total, conjugated and unconjugated bilirubin in serum of control and
arameters Group 1
Control
Group 2
Lycopene
otal bilirubin 0.45 ± 0.02 0.46 ± 0.0
onjugated (direct) bilirubin 0.36 ± 0.03 0.35 ± 0.0
nconjugated (indirect) bilirubin 0.09 ± 0.01 0.09 ± 0.0
alues are expressed as mean ± SD for six rats in each group. aAs comparedgroup 3 (D-GalN/LPS); represent P < 0.05. (Ly- lycopene).
of rats. Diminished levels (P < 0.05) of blood glucose
and glycogen were observed in addition to significantly
elevated levels (P < 0.05) of lactate and pyruvate in liver
upon d-GalN/LPS induction (Group 3) when compared
to control (Group 1). Administration of lycopene (Group
4) before d-GalN/LPS injection brought back the above
changes to near normal. Significant variations were not
found in lycopene alone treated rats (Group 2) when
compared to control.
experimental groups of rats.
alone
Group 3
DGalN/LPS
Group 4
Lycopene + DGalN/LPS
2 0.85 ± 0.06a 0.58 ± 0.03b
2 0.45 ± 0.02a 0.39 ± 0.02b
1 0.40 ± 0.03a 0.19 ± 0.01b
with group 1, bas compared with group 3; a,bP < 0.05.
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Fig. 5. Levels of lactate and pyruvate in control and experimental group
product of nitrogen metabolism. Krebs et al., [30] haveof animals. Values are expressed as mean ± SD for six rats in each
group. a As compared with group 1 (control), b As compared with
group 3 (D-GalN/LPS); a,b represent P < 0.05. (Ly-lycopene).
3.4. Iron and ferritin
Table 2 shows the levels of iron and ferritin in con-
trol and experimental groups of rats. The level of iron
and ferritin was significantly (P < 0.05) increased in d-
GalN/LPS induced rats (Group 3) when compared with
control rats (Group 1). Upon pretreatment with lycopene
(Group 4), the increased levels of iron and ferritin were
brought back to near normal. There was no change in
the levels of these parameters in rats treated alone with
lycopene (Group 2) when compared to control.3.5. Marker enzymes
Table 3 represent the effect of lycopene on the activ-
ities of marker enzymes (AST, ALT, ALP, ACP, GT
Table 2
Levels of iron and ferritin in liver of control and experimental groups of rats.
Parameters Group 1
Control
Group 2
Lycopene alone
Iron 149.13 ± 13.92 149.12 ± 13.92
Ferritin 37.88 ± 3.81 37.60 ± 3.75
Values are expressed as mean ± SD for six rats in each group. aAs compared
Table 3
Activities of aspartate transminase (AST), alanine transaminase (ALT), alka
control and experimental groups of rats.
Parameters Group 1
Control
Group 2
Lycopene alone
AST 5.52 ± 0.48 5.53 ± 0.48
ALT 11.23 ± 1.12 11.15 ± 1.11
ALP 2.28 ± 0.24 2.24 ± 0.23
-GT 5.48 ± 0.52 5.46 ± 0.51
LDH 4.22 ± 0.41 4.20 ± 0.40
Values are expressed as mean ± SD for six rats in each group. aAs comparedniversity for Science 7 (2013) 8–16
and LDH) in liver of control and experimental groups
of rats respectively. Abnormal increase (P < 0.05) in
marker enzymes was observed in d-GalN/LPS induced
rats (Group 3) when compared to control rats (Group 1).
The enzymic activities were found to be at normal when
pretreated with lycopene (Group 4). There seems to be no
significant difference between the lycopene alone treated
rats (Group 2) and control.
3.6. Hematoxylin and eosin staining
Histological analysis of liver section is illustrated
in Fig. 6. Liver section of control and lycopene alone
treated samples shows the normal architecture (a and
b), where as DGalN/LPS induced (group3) liver section
shows extensive cellular necrosis with loss of architec-
ture (c). Lycopene pretreated group 4 sample shows the
recovering cells and reduced necrosis (d).
4. Discussion
In hepatic injury, plasma urea declines significantly
due to failure of the liver to convert amino acids
and ammonia to urea. Several studies have reported
decreased levels of urea during d-GalN-induced hepati-
tis in rats [2]. The results of our study coincide with the
above findings. Urea production is related to metabolic
pathways for disposal of ammonia, which is the toxic endsuggested that stoichiometric amounts of aspartate and
carbamoyl phosphate are required for proper functioning
of the urea cycle. Thus the reduction in the level of urea
Group 3
DGalN/LPS
Group 4
Lycopene + DGalN/LPS
323.22 ± 31.78a 175.53 ± 15.31b
54.06 ± 2.15a 39.42 ± 3.51b
with group 1, bas compared with group 3; a,bP < 0.05.
line phosphatase (ALP) and lactate dehydrogenase (LDH) in liver of
Group 3
DGalN/LPS
Group 4
Lycopene + DGalN/LPS
7.82 ± 0.69a 5.98 ± 0.54b
17.28 ± 1.55a 12.11 ± 1.22b
4.58 ± 0.42a 2.79 ± 0.31b
12.27 ± 1.21a 6.07 ± 0.59b
7.57 ± 0.69a 4.96 ± 0.51b
with group 1, bas compared with group 3; a,bP < 0.05.
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Fig. 6. Histopathological examination of liver sections in control and experimental group of animals (haematoxylin and eosin staining, 100x).
(a). Illustrates a section of control rat showing normal architecture. (b). Illustrates a section of lycopene alone treated rat showing normal liver
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carenchyma with central vein and cords of hepatocytes. (c). Illustrate
ell necrosis extending to the central zone. (d). Illustrates a section
entral vein surrounded by hepatocytes with sinusoidal dilatation with
ay be due to the interference of d-GalN/LPS with the
ontrol mechanisms, which regulate the stoichiometric
ormation of these compounds. Alteration in the levels
f ammonia and urea are potential markers of free radi-
al damage to protein. There is an increased catabolism
f proteins coupled with the diminished ability of kid-
eys to excrete nitrogenous waste. This could possibly
ccount for the raised ammonia and lowered urea lev-
ls in the plasma of d-GalN-induced rats [53]. Uric acid,
he metabolic end product of purine metabolism has been
roven to be a selective antioxidant capable especially of
eacting with free radicals and hydrochlorous acid [18].
ecreased levels of uric acid might be due to increased
roduction of free radicals and subsequent lipid perox-
dation. Creatinine is more readily excreted by kidney
han urea or uric acid. Elevated levels of serum creat-
nine can be attributed to the increased breakdown of
reatine phosphate for energy and conversion of crea-
ine to creatinine for excretion. The restoration of the
bove parameters to near normal in lycopene pretreated
roup 4 rats could be due to the antioxidant defense of
ycopene [6,56,5] that stabilizes the liver function and
ontributes to its anti-hepatotoxic potential [21,61].ion of D-Gal/LPS induced liver which shows loss of architecture and
ver pretreated with lycopene prior to D-Gal/LPS challenge showing
atic necrosis.
Determination of serum bilirubin serves as an index
for the assessment of hepatic function and any abnormal
increase in the levels of bilirubin in the serum indicate
hepatobiliary disease and severe disturbance of hepato-
cellular function. The increased levels of unconjugated
and conjugated bilirubin could result from an impairment
of uptake or conjugation coupled with decreased excre-
tion of the pigment. Increased levels of bilirubin in this
study are in agreement with the reports of the previous
studies that d-GalN-induced hepatitis is characterized
by increased levels of bilirubin in serum [32,54]. The
lycopene mediated suppression of the increased biliru-
bin level suggests the possibility of lycopene being able
to stabilize biliary dysfunction.
The striking feature of d-GalN/LPS-induced hep-
atitis is a significant depletion of liver glycogen and
hypoglycemia. Since liver contain a full complement of
the necessary enzymes involved in glucose homeosta-
sis, toxic drugs may alter the glucose level. Observation
of significant decrease in blood glucose levels during
d-GalN induction has been already reported [34]. Arai
et al. [32], has suggested that, in d-GalN-induced liver
failure model, hepatic glucose production is completely
aibah U14 S.A. Sheriff, T. Devaki / Journal of T
arrested and the liver switches to a glycolytic mode
even in a fasted animal. d-GalN causes the activation
of pyruvate kinase and the glycolysis pathway. The
switch from gluconeogenesis to glycolysis may be due
to the depletion of ATP and probable accumulation of
AMP in liver tissue as a result of fulminant hepatic fail-
ure. Hypoglycemia during liver injury is a consequence
of impaired gluconeogenesis and inability to mobilize
glycogen stores. In the present study the depleted glu-
cose level in group 3 rats was appreciably improved in
group 4 rats pretreated with lycopene suggesting that
it may improve gluconeogenesis. The significant deple-
tion in the levels of liver glycogen in rats given the
hepatotoxin might be due to the rapid and extensive
depletion of UTP, thereby not allowing the cycling of
uridine nucleotides and consequently disrupting sugar
and mucopolysaccharide metabolism. Thus the pathway
leading to glycogen synthesis is diverted to glycolysis in
injured liver since both pathways utilize glucose as the
substrate. Our results suggest that group 4 rats pretreated
with lycopene exhibited considerable prevention in the
excessive depletion of liver glycogen. Administration of
lycopene may protect the liver cells from injury [8] and
stimulate them to convert more glucose to glycogen and
hence glycogen content is restored to near normal levels.
Pyruvate is the major physiological substrate for glu-
coneogenesis and hence impaired gluconeogenesis has
been reported to result in the accumulation of lactate and
pyruvate [45]. It was reported that with the induction of
glycolysis in fulminant hepatic failure rat livers, there
was no concomitant activation of pyruvate dehydroge-
nase to convert pyruvate to acetyl-CoA, which led to a
significant increase in lactate release [3]. Pretreatment
with lycopene prior to d-GalN/LPS induction showed a
significant tendency for the maintenance of lactate and
pyruvate in a near normal range. This may be brought
about by a profound influence of lycopene on the vital
enzymes of liver metabolism. These findings suggest the
protective role of lycopene on cell membrane and on
aberrant activities of carbohydrate metabolism.
Ferritin is valuable indirect marker of stored iron in
liver parenchyma with different types of liver damages.
Thus the evaluation of iron and ferritin levels is a valid
tool during liver injury [20]. The increased level of fer-
ritin and iron during hepatic injury was observed earlier
[43,58,37] Our observation matches with the earlier
findings and lycopene pretreated group 4 animals were
able to restore the near normal values of iron and ferritin
in comparison with group 1 control animals. Since iron
is a reactive metal ion involved in damage to cellular
macromolecules caused by oxygen radicals, its reduc-
tion from Fe3+ to Fe2+ state plays a major role in lipidniversity for Science 7 (2013) 8–16
peroxidation. Thus lipid peroxidation requires the pres-
ence of Fe2+ ion. As the concentration of iron increases,
it finally accumulates in the liver. The tendency for
the restoration of altered levels of iron and ferritin in
rats treated with lycopene prior to the induction of
hepatitis implicates the inhibitory effect of lycopene on
lipid peroxidation chain reaction due to its well known
antioxidant property [5].
Characteristic changes in the enzyme activities dur-
ing hepatic injury induced by d-GalN/LPS have been
reported earlier [31]. The increased activities of these
enzymes indicate cellular leakage and loss of functional
integrity of cell membrane in liver. A significant increase
in the activities of AST, ALT, ALP, LDH and -GT in
this study may be interpreted as a result of the liver
cell destruction or changes in the membrane perme-
ability indicating the severity of hepatocellular damage
induced by d-GalN/LPS, which is in accordance with the
previous reports our laboratory and others [21,52,55].
Pretreatment with lycopene in group 4 rats attenuated
the increased activities of marker enzymes caused by
d-GalN/LPS. This observation coincides with earlier
findings [5] suggests that lycopene promotes parenchy-
mal cell regeneration in liver, thus protecting membrane
fragility thereby decreasing enzyme leakage and restor-
ing the normal liver cell integrity. The histopathological
analysis confirms the above findings.
5. Conclusions
Despite numerous studies on the health benefits
of a carotenoid antioxidant lycopene, it has not been
exclusively studied for its hepatoprotective potential par-
ticularly during hepatitis. The present study explores
the ability of lycopene to protect the liver function dur-
ing chemically induced liver injury in animal model.
Liver damage induced by d-GalN generally reflects
disturbances of liver cell metabolism resulting the
derangement in the values of various metabolites of liver
and in the activities liver marker enzymes. The results of
the present investigation clearly reveal that the adminis-
tration lycopene helps to restore the altered liver function
during experimentally induced hepatitis. This protective
ability of lycopene may be attributed by its well known
antioxidant defense.
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